CompletedPhase 1NCT02914171
Study of Autologous Bone Marrow Derived Mononuclear Cells for Treatment of Ebstein Anomaly
Studying Ebstein malformation of the tricuspid valve
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Timothy J. Nelson
- Principal Investigator
- Muhammad Y Qureshi, MBBSMayo Clinic
- Intervention
- Autologous Bone Marrow-derived Mononuclear Cells(biological)
- Enrollment
- 10 enrolled
- Eligibility
- 30 years · All sexes
- Timeline
- 2016 – 2021
Study locations (1)
- Mayo Clinic, Rochester, Minnesota, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02914171 on ClinicalTrials.gov